Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : EA Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.
Product Name : AJM300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2021
Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : EA Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
